Drug intelligence / Profile preview

VMD-102

Development stage: Phase 2
Lead developer: Vm Discovery
Modality: Small Molecules
Administration: Oral

Overview

VMD-102 is an orally bioavailable, selective small molecule inhibitor of protein kinase C epsilon (PKCε), developed by VM Discovery. PKCε is a member of the novel PKC subfamily and is frequently overexpressed in various cancers, where it promotes cell survival, proliferation, and metastasis. VMD-102 is the first selective PKCε inhibitor to enter clinical testing. It is currently being evaluated in a Phase 1/2 study for the treatment of advanced solid tumors, including hepatocellular carcinoma (HCC), metastatic uveal melanoma, renal cell carcinoma, non-small cell lung cancer, and colorectal cancer.

Targets

PRKCE (Protein Kinase C epsilon)

Beyond the preview

Go deeper on VMD-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VMD-102.

Explore the full profile